Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Advanced Nonhematologic Malignancies 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Somatostatinoma 1Sarcoma, Synovial 1Sarcoma 1Recurrent Lung Squamous Cell Carcinoma 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Non-hematologic Malignancy 1Neurofibrosarcoma 1Neoplasm Metastasis 1Metastatic Castration-Resistant Prostate Cancer 1Meningeal Neoplasms 1Lymphoma 1Liver Neoplasms 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hematologic Neoplasms 1Glioblastoma 1Fibrolamellar hepatocellular carcinoma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1

Interventions

Gemcitabine 47Cisplatin 32pembrolizumab 28Paclitaxel 13Docetaxel 13avelumab 12Mitomycin 12atezolizumab 11Nivolumab 11Cystectomy 10Carboplatin 9durvalumab 7Sunitinib 7apaziquone 6Doxorubicin 6BCG Vaccine 65-aminolevulinic acid hexyl ester 6Vinblastine 5Radiation 5Platinum 5Methotrexate 5Magnetic Resonance Spectroscopy 5Albumin-Bound Paclitaxel 5Taxes 4Standard of Care 4Sorafenib 4Radiotherapy 4Fluorouracil 4Erlotinib Hydrochloride 41,2-diaminocyclohexaneplatinum II citrate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Urinary Bladder Neoplasms × sapanisertib × Clear all
NCT03047213 2026-05-13

Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

National Cancer Institute (NCI)

Phase 2 Active not recruiting
17 enrolled 11 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡